Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Astrocytoma × Lomustine × Clear all

Phase

Status

Completed 9 Unknown 3 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 4 Recurrence 2 Medulloblastoma 2 Lymphoma, Follicular 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Glioma 1 Burkitt Lymphoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Temozolomide 16 Bevacizumab 5 Filgrastim 4 vocimagene amiretrorepvec 3 sargramostim 3 antineoplaston AS 2-1 3 antineoplaston A10 3 Radiotherapy 3 O(6)-benzylguanine 3 Melphalan 3 Flucytosine 3 Dynamic Contrast Enhanced Magnetic Resonance Imaging 3 Aminolevulinic Acid 3 tovorafenib 2 etoposide phosphate 2 cabozantinib 2 Topotecan 2 Thiotepa 2 Surgical Procedures, Operative 2 Radiotherapy, Intensity-Modulated 2 Perfusion Magnetic Resonance Imaging 2 Irinotecan 2 Granulocyte Colony-Stimulating Factor 2 Gadolinium DTPA 2 Etoposide 2 Doxorubicin 2 Dexamethasone 2 Carmustine 2 Calcium Dobesilate 2 Busulfan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02414165 2020-02-07

Toca5

Tocagen Inc.

Phase 2/3 Terminated

Astrocytoma, Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡